Premium
Impact of nevirapine or efavirenz co‐administration on ritonavir‐boosted amprenavir pharmacokinetics in HIV‐infected patients
Author(s) -
Dailly Eric,
Raffi François,
Biron Charlotte,
Allavena C.,
Jolliet P.
Publication year - 2008
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2007.00556.x
Subject(s) - nevirapine , efavirenz , amprenavir , ritonavir , pharmacokinetics , pharmacology , medicine , virology , human immunodeficiency virus (hiv) , reverse transcriptase inhibitor , chemistry , sida , viral disease , antiretroviral therapy , viral load , enzyme , protease , biochemistry , hiv 1 protease
The influence of nevirapine or efavirenz co‐administration on ritonavir‐boosted amprenavir pharmacokinetics was investigated in HIV‐infected patients with a population pharmacokinetic approach. The analysis was performed with a population of 61 patients treated with fosamprenavir/ritonavir (700 mg/100 mg twice daily) combined with nucleoside/nucleotide reverse transcriptase inhibitors ± enfuvirtide and no other antiretroviral drugs (group A, n = 46) or nevirapine (group B, n = 10) or efavirenz (group C, n = 5). No significant increase in amprenavir clearance [mean ± standard deviation: 22.49 ± 10.32 (group A) vs. 21.57 ± 9.62 (group B) vs. 20.15 ± 5.18 (group C) L/h] and no significant decrease in trough amprenavir plasma concentrations [1.75 ± 0.95 (group A) vs. 1.82 ± 0.72 (group B) vs. 1.55 ± 0.66 (group C) mg/L] were found in groups B and C in comparison with group A, although nevirapine and efavirenz are inductors of protease inhibitors metabolism. These results suggest that fosamprenavir/ritonavir should be used at standard doses of 700 mg/100 mg twice daily when combined with efavirenz or nevirapine.